ABCL vs GMAB: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

GMAB is the larger of the two ($31.36B market cap): the incumbent the market prices for continued execution (32.19x forward earnings, beta 0.52). ABCL is the smaller challenger ($3.26B), still expected to post a loss next year: more room to run, but more to prove. On the numbers, GMAB leads on both counts: faster expected revenue growth (21% vs 14%) and expected profits next year, which ABCL does not have. The case for ABCL rests on its own driver (ABCL-635 heads toward late-stage trials): if you believe in that, ABCL fits; if you believe in what the numbers show today, GMAB does.

ABCL vs GMAB: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricABCLGMABWhat it tells you
Market cap$3.26B$31.36BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-14.1732.19Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.590.52Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range59% of range75% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book3.065.08How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how ABCL and GMAB affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABCL and GMAB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABCL and GMAB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does AbCellera Biologics (ABCL) do?

AbCellera Biologics (Nasdaq: ABCL) built an AI-assisted, single-cell antibody-discovery platform (spun out of the University of British Columbia) that it originally rented to pharma partners such as Eli Lilly, Regeneron, AbbVie and Biogen in exchange for research fees, milestones and downstream royalties. Since 2023 it has deliberately scaled back partnership volume to redirect resources into its own internal pipeline, moving from a services-and-royalties model toward being a clinical-stage drug developer that captures more of the upside if its molecules succeed.

Full ABCL guide

What does Genmab (GMAB) do?

Genmab A/S, founded in 1999 and headquartered in Copenhagen, engineers therapeutic antibodies and has historically licensed them to larger partners rather than selling them itself. The best known is daratumumab, sold by Johnson & Johnson as DARZALEX and DARZALEX FASPRO, which has become a backbone therapy in multiple myeloma and pays Genmab a royalty on worldwide net sales. Genmab also earns royalties on ofatumumab (Kesimpta, Novartis) and teprotumumab (TEPEZZA), and shares in two commercial products it helped develop: epcoritamab, sold as EPKINLY in the US and TEPKINLY in Europe with AbbVie, and tisotumab vedotin (TIVDAK) with Pfizer. The strategic shift under way is toward owning products outright. Rina-S (rinatabart sesutecan), a folate receptor alpha antibody-drug conjugate in ovarian cancer, is wholly owned, and the December 2025 close of the $8 billion all-cash acquisition of Merus N.V. at $97 per share added petosemtamab, a late-stage bispecific in head and neck cancer.

Full GMAB guide

ABCL vs GMAB: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ABCL drivers: ABCL-635 heads toward late-stage trials; Deep cash runway.
  • GMAB drivers: DARZALEX royalties still compounding; EPKINLY as the first real commercial franchise.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: AbCellera is unprofitable and burning cash at the operating level, posting a net loss of about $41M in Q3 2026 on about $10.6M of quarterly revenue, so the market value rests on future clinical success, not current earnings. For GMAB, revenue concentration is the first-order risk: DARZALEX royalties were roughly 64% of first-half 2026 revenue, Genmab does not control how the drug is priced or promoted, and daratumumab exclusivity does not last forever, so the whole equity story is a race between pipeline conversion and eventual biosimilar erosion.

ABCL or GMAB: which should you pick?

If the story you believe is ABCL's (ABCL-635 heads toward late-stage trials), ABCL is the more direct way to own it; if it is GMAB's (DARZALEX royalties still compounding), GMAB is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABCL and GMAB guides.

ABCL vs GMAB: the full fundamentals

ABCL. AbCellera has no P/E because it is unprofitable, so investors typically frame it on cash-versus-market-cap and pipeline optionality. After the offering, cash covers about a quarter of the roughly $3.2B market value, up from about a seventh in October, as the share price fell and the cash pile grew, so most of the price still reflects expectations for ABCL-635. Analysts remain upbeat, with an average target near $18.69 across 13 analysts and a strong buy consensus.

GMAB. Figures are approximate and tied to the asOf date; verify live numbers before acting. Genmab is consistently profitable because the royalty line carries almost no cost, but trailing net income of about $729 million now absorbs the interest and operating costs of the Merus acquisition, which is why earnings fell while revenue grew. After rising about 48% over three months on three positive Phase 3 readouts, the ADS trades near 7.3x sales and about 32x forward earnings, so the multiple now carries far more pipeline expectation than it did in the summer. The 11 analysts tracked by Yahoo Finance have a mean target of about $65.

Headline figures (approximate, November 2026): ABCL shows market cap ~$3.2B, share price (nov 20, 2026) ~$9.93, revenue (ttm) ~$68M, revenue (q3 2026) ~$10.6M (up ~19% yr-ago); GMAB shows revenue (ttm) ~$4.3 billion, presented in US dollars (nine-month 2026 revenue up ~22% year over year), darzalex net trade sales (q3 2026) ~$4.24 billion worldwide, on which Genmab earns a royalty, epkinly net sales (9m 2026) ~$491 million, up ~47%, margins (ttm) ~93% gross, ~31% operating, ~17% net.

The bottom line: ABCL vs GMAB

ABCL and GMAB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ABCL and GMAB exposure against your real portfolio. It is not an investment adviser.

Wondering how ABCL or GMAB fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about AbCellera Biologics

Ask Walnut's AI anything about ABCL and see how it fits what you own.

FAQ

What is the difference between ABCL and GMAB?

+

AbCellera Biologics (Nasdaq: ABCL) built an AI-assisted, single-cell antibody-discovery platform (spun out of the University of British Columbia) that it originally rented to pharma partners such as Eli Lilly, Regeneron, AbbVie and Biogen in exchange for research fees, milestones and downstream royalties. Genmab A/S, founded in 1999 and headquartered in Copenhagen, engineers therapeutic antibodies and has historically licensed them to larger partners rather than selling them itself. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ABCL or GMAB the better stock?

+

Neither is universally better. GMAB is the larger incumbent; ABCL is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ABCL or GMAB?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ABCL and GMAB?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ABCL vs GMAB?

+

ABCL: AbCellera is unprofitable and burning cash at the operating level, posting a net loss of about $41M in Q3 2026 on about $10.6M of quarterly revenue, so the market value rests on future clinical success, not current earnings. After a roughly 190% gain in 2026 the stock carries high expectations for ABCL-635, and with ABCL-575 shelved after Phase 1 the company is closer to a single-asset story: weaker late-stage data, safety findings (liver monitoring is a known issue in the NK3R class), or competition from approved non-hormonal therapies could sharply reset the valuation. The 2026 offering already diluted holders by about 8% in share count, and late-stage trials are expensive. Platform revenue has fallen far from its pandemic-era peak (when Lilly antibody royalties were large), is lumpy and partner-dependent, and the number of partner-led programs fell to 34 from 44 this year. Drug development carries the usual risks of trial failure, regulatory delay and competition in crowded indications, and while the cash runway is long, sustained losses (analysts expect about -$0.61 EPS for 2026 and -$0.70 for 2027) could eventually require more financing. GMAB: Revenue concentration is the first-order risk: DARZALEX royalties were roughly 64% of first-half 2026 revenue, Genmab does not control how the drug is priced or promoted, and daratumumab exclusivity does not last forever, so the whole equity story is a race between pipeline conversion and eventual biosimilar erosion. Multiple myeloma is also the most crowded field in oncology, with Sanofi's Sarclisa, Pfizer's Elrexfio, and Johnson & Johnson's own TECVAYLI, TALVEY, and CARVYKTI all competing for the same patients that daratumumab treats. EPKINLY faces Roche's Lunsumio and Columvi and Regeneron's odronextamab in lymphoma, and Rina-S enters an ovarian setting where AbbVie's Elahere is already established. The wholly owned pipeline concentrates outcome risk in a small number of readouts, and the Merus deal spent a large share of the balance sheet on one of them: Genmab now carries about $5.2 billion of debt against roughly $1.9 billion of cash. The three October 2026 Phase 3 successes also raise the bar: after a roughly 48% three-month rise, the stock now prices in label expansions and launches that regulators have not yet approved, and any regulatory delay, safety signal in the full data, or slow launch would land on a much higher valuation. AbbVie has also filed a trade secret misappropriation complaint in US federal court touching antibody-drug conjugate technology, which is separate from ordinary commercial risk. Finally, the ADS carries Danish krone exposure and the ordinary share's Copenhagen listing sets the price the ADS tracks.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABCL or GMAB; figures are approximate and dated (as of November 2026). Verify current data before investing.